Anti-Enterovirus 68, Capsid (Clone EV-D68-159) – Purified No Carrier Protein
Anti-Enterovirus 68, Capsid (Clone EV-D68-159) – Purified No Carrier Protein
Product No.: E175
- -
- -
Product No.E175 Clone EV-D68-159 Target Capsid ⋅ Enterovirus D68 Product Type Recombinant Monoclonal Antibody Alternate Names EVD68, Enterovirus, VP1, VP3 Isotype Human IgG1 Applications ELISA , EM , N |
- -
- -
Antibody DetailsProduct DetailsReactive Species Enterovirus D68 Expression Host HEK-293 Cells Immunogen Sequenced from PBMCs from a donor who had recovered from a naturally-occurring Enterovirus D68 infection. Product Concentration ≥1.0 mg/ml Purity ≥90% monomer by analytical SEC and SDS-Page Formulation This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. State of Matter Liquid Product Preparation Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling Antibodies may be stored sterile as received at 2-8°C for up to one year. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≥ -80°C. Avoid Repeated Freeze Thaw Cycles. Regulatory Status Research Use Only Country of Origin USA Shipping 2 – 8° C Wet Ice Additional Applications Reported In Literature ? ELISA, EM, N Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone EV-D68-159 is a human IgG monoclonal antibody specifically binds to VP1
and VP3 of Enterovirus D68, clade B. Background EV-D68 is a highly transmissible respiratory disease that primarily impacts children. It is among the 100-plus non-polio enteroviruses and is listed as a NIAID Biodefense Priority Pathogen. The respiratory condition can vary from mild (resembling a common cold) to more severe, potentially resulting in acute flaccid myelitis (AFM), a condition characterized by lasting muscle weakness. The majority of individuals with EV-D68 encounter mild symptoms and recuperate without significant complications1. No vaccines are currently accessible for preventing EV-D68 infections, but practical measures can aid in lowering the chances of transmission. The virus is transmitted via respiratory secretions (saliva, nasal mucus, and sputum) when an infected individual coughs, sneezes or makes contact with surfaces subsequently touched by others2. Clone EV-D68-159 light chain CDR1 and CDR3 bind to three residues on the C terminus of VP1(Glu271, Arg272, and Asp285); however, the heavy chain CDR2 and and CDR3 bind the N-terminal loop of VP3 before the B-β strand. The capsid is made up of four viral proteins (VP1, VP2, VP3, and VP4) that are crucial for the virus's ability to bind and enter host cells. Clone EV-D68-159 effectively binds and neutralizes clade B virus, preventing it from infecting cells and spreading4. Antigen Distribution Enterovirus-D68 (EV-D68) can be found in human respiratory epithelial
cells, gastrointestinal cells, and motor neurons within the spinal cord's grey matter. Research Area Infectious Disease . Seasonal and Respiratory Infections . Viral . IVD Raw Material References & Citations1. Enterovirus D68 (EV-D68): Symptoms, Treatment & Prevention. Cleveland Clinic. Accessed July 13, 2024. https://my.clevelandclinic.org/health/diseases/21669-enterovirus-d68 2. CDC. About Enterovirus D68. Non-Polio Enterovirus. Published June 7, 2024. Accessed July 13, 2024. https://www.cdc.gov/non-polio-enterovirus/about/about-enterovirus-d68.html 3. Li X, Li Y, Fan S, et al. Discovery and Optimization of Quinoline Analogues as Novel Potent Antivirals against Enterovirus D68. J Med Chem. 2022;65(21):14792-14808. 4. Vogt MR, Fu J, et al. Sci Immunol. 2020;5(49). Technical ProtocolsCertificate of Analysis |
Formats Available
- -
- -
Prod No. | Description |
---|---|
E175 |
Products are for research use only. Not for use in diagnostic or therapeutic procedures.